Chronic Refractive Gout Treatment Posts Positive Topline Results

Selecta Biosciences and Sobi have announced positive topline results from two arms of a late-stage study of their novel investigational combination medicine SEL-212 in adults with chronic refractory gout.

SEL-212 is a combination of Selecta’s ImmTOR immune tolerance platform designed to mitigate the formation of anti-drug antibodies and pegadricase, a therapeutic uricase enzyme, designed to reduce serum urate (SU) levels in people with chronic refractory gout.

The U.S. arm of the study met its primary endpoint, with 56 percent of patients who received monthly doses of SEL-212 achieving a reduction in SU for at least 80 percent of the time during month six.

The global arm also met its primary endpoint, with 47 percent of participants who received a lower dose of the medicine achieving a response.